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Abstract
Background: Diagnosis and treatment of ovarian cancer (OC) entail severe symptom burden and a significant loss
of quality of life (QOL). Somatic and psychological impairments may persist well beyond active therapy. Although
essential for optimal symptom management as well as for the interpretation of treatment outcomes, knowledge
on the course of QOL-related issues is scarce. This study aimed at assessing the course of depressive symptoms,
anxiety, fatigue and QOL in patients with OC over the course of chemotherapy until early after-care.
Methods: 23 patients were assessed longitudinally (eight time points) with regard to symptom burden
(depression, anxiety, fatigue, and QOL) by means of patient-reported outcome instruments (HADS, MFI-20, EORTC
QLQ-C30/-OV28) and clinician ratings (HAMA/D) at each chemotherapy cycle and at the first two aftercare visits.
Results: Statistically significant decrease over time was found for depressive symptoms and anxiety as well as for
all fatigue scales. With regard to QOL, results indicated significant increase for 11 of 15 QOL scales, best for Social
(effect size = 1.95; p < 0.001), Emotional (e.s. = 1.62; p < 0.001) and Physical Functioning (e.s. = 1.47; p < 0.001).
Abdominal Symptoms (e.s. = 1.01; p = 0.009) decreased, Attitudes towards Disease and Treatment (e.s. = 1.80; p <
0.001) improved significantly over time. Analysis of Sexual Functioning was not possible due to a high percentage
of missing responses (61.9%).
Conclusions: The present study underlines the importance of longitudinal assessment of QOL in order to facilitate
the identification of symptom burden in OC patients. We found that patients show high levels of fatigue, anxiety
and depressive symptoms and severely impaired QOL post-surgery (i.e. at start of chemotherapy) but condition
improves considerably throughout chemotherapy reaching nearly general population symptoms levels until
aftercare.
Background
According to GLOBOCAN estimates [1], 224.747
women worldwide were diagnosed with ovarian cancer
(OC) in 2008. Fatally enough, early stage disease usually
presents with minor and unspecific symptoms [2,3],
considerably prolonging the time period between occur-
rence of first complaints and physician consultation.
This circumstance is the major reason why in 75% of
the concerned patients OC is diagnosed at an advanced
stage (i.e. FIGO stages III and IV) [4] and prognosis is
consequently poor. Therefore, OC is called the “silent
killer”. In the majority of cases, treatment involves
cytoreductive surgery with obligatory removal of the
uterus and both adnexa as well as post-operative che-
motherapy. The chemotherapeutic approach usually
consists of a platinum-taxane combination [5] adminis-
tered either intravenously or directly into the peritoneal
cavity [6]. Despite this intensive, burdensome treatment,
patients still have to face a considerable risk of recur-
rence [7].
Advances in the treatment of OC, however, contribute
to increased survival rates. Thus, quality of life (QOL)
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any medium, provided the original work is properly cited.issues are gaining importance for patients and caregivers
extending treatment goals from mere prolongation of
disease-free periods to maintenance of functioning and
well-being. The latter proves challenging in the light of
knowledge about toxicity. OC patients have to deal with
a range of treatment-related symptoms such as hemato-
logical side-effects, gastrointestinal problems, neuro-
pathic pain, menstrual changes together with climacteric
symptoms, and fertility issues [8-10]. Furthermore, the
majority of OC patients experiences fatigue [8,11,12]
severely affecting patients’ daily lives far beyond the
completion of treatment [13]. Accordingly, it was ranked
as the most important symptom by both, patients [14]
and physicians [15].
Other problems, although highly prevalent, are less
communicated during physician consultation. This
applies to a range of QOL issues such as sexual [16]
and emotional difficulties [17]. Routinely conducted
monitoring of symptom burden considerably contributes
to the detection as well as to the systematic investiga-
tion of neglected symptoms and aspects of functioning.
Several studies in this field found OC patients to experi-
ence high levels of distress over delayed diagnoses as
well as anxiety and depression [9,18-21], both good pre-
dictors for global QOL [12]. The role of QOL itself as a
predictor of disease outcome and survival in OC
patients is yet controversially discussed [18,22]. None-
theless, QOL proves essential not only for optimal
symptom management but also as additional informa-
tion in the evaluation of treatment outcomes in clinical
trials. Knowledge, however, on the course of QOL issues
during therapy is scarce in OC patients.
Therefore, this study was designed to assess a wide
range of disease- and treatment-related issues relevant
to OC patients from the beginning of chemotherapy
until early aftercare in a longitudinal approach. Thus, it
addressed the trajectory of depressive symptoms, anxi-
ety, fatigue and QOL in patients with OC.
Methods
Sample
OC patients at the Department of Gynecology and
Obstetrics at Innsbruck Medical University were
included in the study at the beginning of adjuvant intra-
venous chemotherapy.
Additional inclusion criteria comprised: age between
18 and 85 years, expected survival time of at least 3
months, no overt cognitive impairments, fluency in Ger-
man language as well as written informed consent.
Procedure
Patient recruitment started in 2003 and data assessment
was completed in 2006. Eligible patients were
approached by a physician or a psycho-oncologist at
their routine appointments for chemotherapy adminis-
tration and were consecutively included.
Assessments concerning depressive symptoms, anxiety
and fatigue were completed at each chemotherapy cycle
and at the first two aftercare visits (i.e. three and 6
months after termination of the chemotherapy, respec-
tively). QOL, subsuming physical as well as psychosocial
symptoms, was assessed at the first, the third as well as
the sixth chemotherapy cycle and at both aftercare vis-
its. Baseline data was collected post-surgery at first che-
motherapy cycle.
Overall, it was expected to cover a time frame of
about 9 months in each patient. Ethical approval for this
project was obtained from the Ethics Committee of
Innsbruck Medical University.
Assessment instruments
Sociodemographic variables included age, education,
employment and marital status. Clinical data comprised
FIGO stage, histological subtype, presence of residual
disease after primary debulking surgery, number of total
chemotherapy cycles and menopausal status. Data was
gathered from hospital records.
To evaluate progression of physical and psychosocial
symptoms over the course of chemotherapy, we applied
the following assessment instruments.
Hospital Anxiety and Depression Scale (HADS)
The Hospital Anxiety and Depression Scale (HADS) [23]
is a widely used, validated screening instrument for
anxiety and depressive symptoms in somatically ill
patients. It is a short self-assessment scale comprising
14 questions, addressing anxiety and depressive symp-
toms with 7 items each at the time-frame of the pre-
vious 7 days.
Hamilton Anxiety and Depression Scales (HAMA, HAMD)
The Hamilton Anxiety as well as Depression Scales are
semi-structured interviews developed for the clinical
evaluation of severity of anxiety and depression in
adults.
The HAMA [24] consists of 14 items which are
defined by a series of symptoms measuring both psychic
anxiety (mental agitation and psychological distress) and
somatic anxiety (physical complaints related to anxiety).
The HAMD [25] is a 21-item scale evaluating depressed
mood, vegetative and cognitive symptoms of depression
and comorbid anxiety symptoms. It provides ratings on
current DSM-IV symptoms of depression, with the
exceptions of hypersomnia, increased appetite and con-
centration/indecision.
In both interviews items are rated on a five-point
Likert scale, higher total scores indicating more severe
anxiety or depression.
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The MFI-20 [26] is a 20-item self-report instrument
designed to measure fatigue by means of the five sub-
scales General Fatigue, Physical Fatigue, Mental Fatigue,
Reduced Motivation, and Reduced Activity. Each sub-
scale comprises four items that are rated on a five-point
Likert scale, higher scores indicating a higher level of
fatigue.
EORTC Quality of Life Questionnaires (QLQ-C30, QLQ-OV28)
The EORTC QLQ-C30 [27], an internationally validated
and widely used cancer-specific QOL-instrument,
assesses various facets of functioning and symptoms
common in cancer patients. It comprises five function-
ing scales (physical, social, role, emotional, cognitive), a
scale for global QOL, and nine symptom scales (fatigue,
nausea/vomiting, pain, dyspnea, sleeping disturbances,
appetite-loss, constipation, diarrhea, and financial
impact). All scales are scored according to EORTC
guidelines resulting in a score range from 0 to 100
points.
T h eQ L Q - O V 2 8m o d u l e[ 2 8 ]i sas u p p l e m e n to ft h e
QLQ-C30 for assessing issues relevant to ovarian cancer
patients. The module covers abdominal/gastrointestinal
symptoms, peripheral neuropathy, other chemotherapy
side-effects, hormonal/menopausal symptoms, body
image, attitude to disease/treatment and sexual
functioning.
With reference to Osoba et al. [29], differences in
QOL-scores of 10 points or more should were consid-
ered as moderate and differences of 5 to 10 points as
small.
Statistical analysis
Sample characteristics are presented as frequencies, per-
centages, means, standard deviations and ranges.
Longitudinal analyses of the outcome measures were
conducted using mixed linear models, including fixed
effects and random intercepts on patient level. The
sequential numbers of the assessment time points (0 to
7) were included in the model as covariate. Although,
especially with regard to aftercare, time points were not
equidistant, this was considered reasonable to model the
slightly quadratic shape of the regression curve, indicat-
ing slower recovery in aftercare. This quadratic effect
was expected since patients’ condition improved much
until the end of chemotherapy, so that further recovery
was likely to occur in greater intervals. More complex
statistical modeling was not appropriate due to sample
size. Regression weights (beta) are given for significant
fixed effects.
Effect sizes (Cohen’s d) were calculated as difference
between baseline and last assessment divided by baseline
standard deviation.
Results
Patient characteristics
Due to administrative reasons patients could only be
approached randomly. Twenty three patients (30% of eli-
gible patients treated at the Department of Obstetrics
and Gynaecology at Innsbruck Medical University during
the study period) could be recruited at beginning of che-
motherapy. Two patients withdrew consent (due to
expected burden and language difficulties) and were
excluded from statistical analysis. No patient has been
lost to follow-up. Mean patient age was 52.8 years (SD
13.1). The most frequent histopathologic cancer type was
serous carcinoma (66.7%). The most common FIGO
stage was III (76.2%). 20 patients were treated with a car-
boplatine-paclitaxel combination and one patient
received cisplatin/etoposid. 17 patients received 6, one
patient 7 and three patients 9 cycles of first line che-
motherapy. All patients were assessed at the first six
cycles and subsequently, in aftercare. One patient was
diagnosed with recurrent disease during early aftercare.
15 patients (71.4%) received psycho-oncological counsel-
ing at some point during the study (6 patients > 10 visits,
5 patients 5-10 visits, 4 patients < 5 visits). Further details
on patient characteristics are summarized in Table 1.
Time course of depressive symptoms and anxiety
Assessment via self-reports (HADS) as well as via
expert-ratings (HAMA/D) at each chemotherapy cycle
and at the first two aftercare visits revealed a significant
decrease over time for both, the prevalence of depressive
symptoms and anxiety. Effect size was 1.11 for HADS-
Depression, 1.03 for HAM-Depression, 0.93 for HAM-
Anxiety and 0.69 for HADS-Anxiety. For further details
see Table 2 and Figure 1.
Time course of fatigue
A statistically significant decrease over the course of
treatment was found for all MFI scales. The decrease in
terms of baseline standard deviation units was strongest
for Reduced activity (e.s. = 1.85), Physical Fatigue (e.s. =
1.46) and General Fatigue (e.s. = 1.15). Lower but still
significant was the change in Reduced Motivation (e.s. =
0.54) and Mental Fatigue (e.s. = 0.47). Similarly, the
Fatigue scale of the EORTC QLQ-C30 indicated a
strong improvement over time (e.s. = 1.77). For further
details see Tables 3 and 4 as well as Figure 2 depicting
the time course.
Time course of quality of life and symptoms
With regard to the QLQ-C30, significant increase was
found for 11 of 15 Functioning subscales. The improve-
ment was best for Social Functioning (e.s. = 1.95), Emo-
tional Functioning (e.s. = 1.62) and Physical Functioning
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Global QOL (e.s. = 0.90) and Cognitive Functioning (e.s.
= 0.52) were lower, but still significant. Furthermore,
significant improvements were found for Fatigue (e.s. =
1.77), Pain (e.s. = 0.94), Nausea/Vomiting (e.s. = 0.60)
and Financial Impact (e.s. = 0.52).
S i n c ef o rt h es c a l e sA p p e t i t eL o s sa n dD i a r r h e an o n e
of patients reported a value above 0 at the second after-
care visit, this time point had to be excluded from the
mixed linear model due to lack of variance. Whereas,
for Diarrhea no significant time effect was found for the
remaining time points, Appetite Loss decreased signifi-
cantly (e.s. = 1.17).
The Ovarian Cancer Module QLQ-OV28 revealed a
significant decrease in Abdominal Symptoms (e.s. =
1.01) and an improvement for Attitudes towards Disease
and Treatment (e.s. = 1.80). Analysis of the scale Sexual
Functioning was not possible due to a very large num-
ber of missing values (61.9%).
Discussion
Diagnosis and treatment of OC, mostly comprising
debulking surgery and subsequent chemotherapy, entail
severe symptom burden and a significant loss of
patients’ quality of life.
Correspondingly, our study results indicate impair-
ments for a wide range of somatic and psychological
symptoms at the beginning of chemotherapy. Thus, at
baseline, levels of anxiety and the prevalence of depres-
sive symptoms were increased as reflected by self- as
well as proxy-ratings. Similarly, fatigue (in terms of gen-
eral fatigue, physical fatigue and reduced activity) was
found to be high. Patients, however, recovered signifi-
cantly over time up until aftercare. A strong improve-
ment was not only found for anxiety and regarding the
prevalence of depressive symptoms but also for almost
all aspects of functioning covered by the QLQ-C30 as
well as for fatigue (less pronounced for mental fatigue
and reduced motivation). Both HADS as well as MFI-20
scores returned toward general population levels [30,31].
From a clinical point of view, this degree of recovery was
remarkable and unexpected forasmuch as patient-reported
QOL measures correlate with standard toxicity criteria
[32] and provide viable information on the impact of treat-
ment-related toxicity on patients’ functioning. Other stu-
dies, however, report similar pronounced improvements of
QOL in OC patients during chemotherapy until one year
follow-up as found in this study [33-36].
Unfortunately, the small sample size did not allow for
detailed subgroup analyses, which is the major limitation
of the study. Thus, it was not possible to investigate if
the observed QOL-scores can be attributed to response
to treatment. Bezjak et al. [33], however, surmise that
the improvement of QOL is not an effect in treatment
responders only but can as well be observed in cancer
patients with stable disease.
One possible explanation for the improvement of
QOL in the course of treatment is the choice of base-
line. In studies on QOL in OC patients, assessing base-
line scores post-surgically is considered as standard.
Von Gruenigen et al. [34], though, suggest low QOL at
the beginning of chemotherapy to be an effect of sur-
gery and, in accordance with Bezjak et al. [33], discuss
this low post-operative baseline as the potential reason
for rapid QOL improvement.
This interpretation might also apply for the present
study. Since baseline scores were assessed at beginning of
Table 1 Descriptive statistics for sociodemographic and
clinical variables of the 21 eligible patients with ovarian
cancer at the time of study inclusion before the initiation
of adjuvant chemotherapy
n%
Age [in years] mean (SD)
range
52.8 (13.1)
27-74
Education compulsory school or less 15 71%
apprenticeship/professional 2 10%
school
A-level/university 4 19%
Marital status single 1 5%
married/with partner 16 75%
divorced/separated 2 10%
widowed 2 10%
Employment status full employment 4 19%
part-time employment 6 29%
homemaker 6 29%
retired/pension 4 19%
other 1 5%
Menopausal status pre-menopausal 9 43%
post-menopausal 12 57%
FIGO stage I-II 6 27%
III-IV 15 73%
Histological
subtype
mucinoid carcinoma 3 14%
serous carcinoma 16 76%
endometrioid carcinoma 1 5%
other 2 10%
Residual disease none 7 33%
yes 12 57%
missing 2 10%
Chemotherapy
regimen
carboplatin/paclitaxel 20 95%
cisplatin/etoposide 1 5%
Chemotherapy
cycles
61 7 81%
71 5%
93 14%
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assessment instruments
BL
a CT2
b CT3 CT4 CT5 CT6 AC1
b AC2 Constant Term/
Beta Coefficient
Reference
Values
c
Hospital Anxiety and Depression Scale (HADS)
c
Anxiety 7.0 (4.2) 6.1 4.5 4.5 3.9 4.1 4.5 4.1 (4.3) 5.7/-0.3 t = -2.80; p = 0.006 5.0 (3.4)
Depression 6.5 (3.8) 5.4 3 4.5 3.5 3.3 3.1 2.3 (3.6) 5.2/-0.3 t = -4.07; p < 0.001 4.7 (3.9)
Hamilton Anxiety and Depression Scale (HAMA/D)
Anxiety 15.0 (8.0) 11.0 11.4 10.4 8.3 7.5 9.2 7.6 (5.9) 12.8/-0.6 t = -3.01; p = 0.004 n.a.
Depression 11.7 (6.8) 8.1 7.9 7.6 5.6 6.6 5.2 4.7 (3.2) 9.3/-0.6 t = -3.58; p = 0.001 n.a.
Multidimensional Fatigue Inventory (MFI)
c
General
Fatigue
13.2 (4.7) 13.4 11.9 12.8 11.8 11.7 9.7 7.8 (3.9) 13.4/-0.5 t = -4.62; p < 0.001 10.8 (3.7)
Physical
Fatigue
13.1 (3.9) 13.5 13.4 12.9 11.2 11.2 9.6 7.4 (4.4) 13.7/-0.5 t = -5.29; p < 0.001 11.1 (4.2)
Reduced
Activity
15.4 (4.8) 15.1 12.2 12.4 10.9 11.2 8.7 6.5 (3.6) 15.2/-1.0 t = -8.19; p < 0.001 10.5 (4.0)
Reduced
Motivation
7.5 (3.5) 7.4 6.5 7.9 6.4 6.3 6.2 5.6 (1.9) 7.5/-0.2 t = -2.98; p = 0.004 9.9 (3.5)
Mental
Fatigue
9.8 (5.1) 8.6 8.8 9.6 8.2 7.7 7.5 7.3 (4.3) 9.3/-0.2 t = -2.03; p = 0.046 9.2 (3.4)
a BL baseline (CT1)
b CT chemotherapy cycle, AC aftercare
c Reference values: HADS (female general population) [31]MFI-20 (general population > 60 y) [30]
Figure 1 Time course of anxiety and depressive symptoms in the 21 patients with ovarian cancer as assessed with the Hospital
Anxiety and Depression Scale (HADS) and the Hamilton Anxiety and Depression Scale (HAM).
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gery, high somatic and psychosocial symptom burden
resulting in low QOL was expected due the burdensome
circumstances of this specific treatment period. As che-
motherapy has to start without delay, patients are usually
not discharged from hospital after surgery, thereby coun-
teracting patients’ desire to regain strength and activate
resources in their familiar surroundings at home.
This fearful anticipation of a probably fatal outcome is
mingled with the fear of chemotherapy and its expected
side-effects. Furthermore, the impact of surgery on QOL
c o u l da l s ob ei n f l u e n c e db yt u m o rs t a g ea n dt h u s ,t h e
extent of the surgical intervention but also by intra- or
postoperative complications. In our sample, distribution
of tumor stage can be considered as representative for
the population of OC patients [1].
Table 3 Course of Quality of Life as assessed in 21 ovarian cancer patients with the EORTC Quality of Life core
questionnaire (QLQ-C30)
EORTC QLQ-C30
c
Baseline
a CT3
b CT6 AC1
b AC2 constant term/
beta coefficient
Physical Functioning (PF) 53.7 (27.3) 62.0 65.9 78.5 93.9 (8.7) 50.1/5.9 t = 7.31; p < 0.001
Social Functioning (SF) 34.1 (26.6) 53.9 63.7 76.5 86.1 (15.6) 34.3/7.2 t = 7.29; p < 0.001
Role Functioning (RF) 40.5 (35.2) 36.3 47.1 62.0 77.8 (27.8) 32.0/5.0 t = 3.74; p < 0.001
Emotional Functioning (EF) 47.6 (24.6) 64.2 69.6 79.9 87.5 (15.7) 49.0/5.3 t = 5.93; p < 0.001
Cognitive Functioning (CF) 77.0 (25.5) 73.5 86.3 86.3 90.3 (16.6) 75.0/2.0 t = 2.22; p = 0.031
Global QOL (GQOL) 47.5 (14.3) 56.4 59.8 58.3 60.4 (29.3) 49.0/1.9 t = 2.405; p = 0.019
Fatigue (FA) 66.1 (28.2) 51.6 51.6 33.3 16.2 (16.8) 67.2/-6.3 t = -6.18; p < 0.001
Nausea/Vomiting (NV) 23.8 (30.1) 15.6 14.7 2.8 5.6 (13.0) 23.1/-3.0 t = -3.35; p = 0.002
Pain (PA) 46.0 (37.6) 35.3 33.3 25.9 10.6 (13.5) 47.9/-4.8 t = -4.18; p < 0.001
Dyspnoe (DY) 19.0 (34.3) 13.7 23.5 7.4 8.3 (20.7) 18.5/-1.5 t = -1.36; p = 0.178
Sleeping Disturbances (SD) 38.1 (38.4) 35.3 23.5 55.6 13.9 (33.2) 39.5/-3.1 t = -1.91; p = 0.062
Appetite Loss (AP) 57.1 (42.4) 5.9 21.6 7.4 0.0 (0.0) 31.0/-4.0 t = -3.04; p = 0.006
Constipation (CO) 25.0 (35.7) 15.7 27.5 14.8 6.1 (20.1) 23.9/-2.0 t = -1.60; p = 0.116
Diarrhea (DI) 16.7 (29.6) 11.8 8.3 9.3 0.0 (0.0) 12.2/-0.7 t = -1.43; p = 0.167
Financial Impact (FI) 19.0 (30.9) 25.5 13.7 5.9 2.8 (9.6) 23.8/-2.9 t = -3.12; p = 0.003
a Baseline (CT1)
b CT chemotherapy cycle, AC aftercare
c Reference values (general German population, female) [53]: PF = 88.7 (17.5), SF = 90.3 (20.1), RF = 86.6 (23.7), EF = 76.3 (22.2), CF = 90.1 (18.4), GQOL = 69.2
(21.9); FA = 19.5 (23.1), NV = 3.6 (11.4), PA = 17.2 (25.3), DY = 9.1 (21.6), SD = 19.1 (29.0), AP = 6.3 (17.4), CO = 4.3 (14.9), DI = 3.1 (12.6), FI = 6.3 (18.6)
Table 4 Course of Symptoms as assessed in 21 ovarian cancer patients with the ovarian cancer-specific module (OV-
28) of the EORTC Quality of Life core questionnaire
EORTC QLQ-OV28
c
Baseline
a CT 3
b CT 6 AC1
b AC2 constant term/
beta coefficient
Abdominal Symptoms (AS) 41.9 (28.1) 21.8 29.2 20.5 13.5
(21.7)
36.8/-3.0 t = -2.72; p = 0.009
Peripheral Neuropathy (PN) 32.8 (26.2) 37.7 39.2 37.7 23.1 (26.1) 35.3/-0.5 t = -0.39; p = 0.697
Other Chemotherapy-related Side Effects (CSE) 30.2 (33.8) 29.3 29.8 23.0 1.6
(2.7)
42.4/-5.7 t = -5.97; p < 0.001
Hormonal/menopausal Symptoms (HS) 34.1 (35.1) 22.2 26.5 31.5 22.2 (31.2) 30.2/-0.8 t = -0.55; p = 0.587
Body Image (BI) 73.0 (33.1) 74.5 84.3 75.0 77.8 (25.0) 74.2/0.8 t = 0.68; p = 0.502
Attitudes towards Disease
and Treatment (AT)
26.1 (22.6) 39.5 56.9 53.7 66.7 (24.6) 27.1/5.4 t = 5.30; p < 0.001
Sexual Functioning (SF) 47.9 (21.9) 64.3 48.8 57.3 57.4 (12.8) 48.9/1.0 n = 8
a Baseline (CT1)
b CT chemotherapy cycle, AC aftercare
c Reference values (ovarian cancer patients, all stages) [54]: AS = 21.9 (22.1), PN = 17.1 (27.2), CSE = 19.5 (20.5), HS = 25.8 (30.3), BI = 22.2 (27.4), AT = 42.3 (30.6)
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the actual initiation of adjuvant chemotherapy, which
introduces a structured course of events into the
patient’s clinical daily life. The patient works towards a
foreseeable end of treatment, gaining a feeling of secur-
ity from the well-regulated procedure, which supports
adjustment to the current situation. Moreover, OC
patients may very well compensate decreased function-
ing and well-being with increased social support [37].
Other psychological factors may also contribute to the
increase of QOL scores in ovarian cancer patients to a
level similar to general population norms.
T h ei m p o r t a n c eo fp a t i e n t s ’ expectations in the con-
text of evaluation of QOL has already been pointed out
by Wan et al. [38] who demonstrated that the discre-
pancy between what patients expect and what actually
occurs with treatment is a significant predictor for every
dimension of health-related QL. The expectation of cure
or at least, prolongation of survival, which is more pro-
nounced in the active stage of treatment, might play an
important role. Doyle et al. [39] found that 65% of the
27 women with advanced ovarian cancer expected che-
motherapy to prolong their survival and 42% to cure
them. However, negative and unrealistic expectations
might also translate into adverse experiences in the
course of treatment [40], which underlines the impor-
tance of assistance in terms of psychooncological sup-
port in order to establish and maintain realistic QOL
expectations [38].
When prior expectations are challenged by actual
treatment experiences, patients’ perspectives might be
altered leading to a possible change in the subjective
appraisal of QOL. This ‘response shift’ is defined as a
process of change in internal standards of measurement,
values and the self-evaluation as well as conceptualiza-
tion of quality of life over the course of the disease tra-
jectory [41]. This model provides a dynamic feedback
loop to explain how quality of life scores can be stabi-
lized despite changes in objective health status [42].
The possibility of response shift should, however, not
blur the fact that “toxicity to which the patient has
accommodated still is toxicity” [43].
After completion of treatment and within the time
frame of aftercare, patients are relieved about having
completed a difficult treatment period. Clinical experi-
ence suggests that levels of psychological distress prob-
ably increase during later aftercare as integration in
medical treatment procedures is less intense and the
Figure 2 Time course of various aspects of fatigue in the 21 patients with ovarian cancer as assessed with the Multidimensional
Fatigue Inventory (MFI-20).
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from a study conducted by Mirabeau et al. [44] investi-
gating long-term adjustment and QOL in survivors after
a minimum of 3 years without recurrence, support the
clinical impression by showing that anxiety when getting
the results of CA-125 relapse-screening is still an issue
for these patients. At a 10-year follow up assessment,
findings by Greimel et al. [22] showed QOL in OC sur-
vivors returning to normal levels, yet in a small sample
only.
Accordingly, one other limitation of the present study
is that follow-up assessment was terminated after 9
months. Continuous assessment beyond early aftercare
might have provided important information on the sta-
bility of the rather good condition at study end point.
Available literature on long-term quality of life in OC
patients, especially in aftercare, is scarce [45] also
because long-term survival rates are rather low.
In addition to distress due to fear of recurrence, OC
survivors often report sexual problems attributed to can-
cer [44,46,47]. Unfortunately in the present investiga-
tion, no analysis of sexual functioning and impairment
was possible given that only a few patients answered the
questions pertaining to this matter. This is, however, a
common difficulty reported in several studies [28,44].
The problem of some issues not being volunteered by
patients is restricted neither to sexual issues nor to
questionnaire assessment. As already mentioned pre-
viously, even the most prevalent symptoms often remain
unaddressed during physician consultation. As a result,
only a certain part of the patients in need receives tar-
geted interventions [8].
Routine QOL assessment can contribute to optimized
symptom management by eliciting unrecognized pro-
blems while monitoring the course of patients’ level of
functioning and well-being. Even more so as self-reports
are reported to be more sensitive to underlying changes
in functional status and are reported sooner than rated
by physicians [48]. To support feasibility in clinical rou-
tine, QOL assessment can be done computer-based,
allowing easy data processing and real-time feedback to
the medical staff [49]. Furthermore, the electronic
approach allows building large datasets which can be
used to calculate specific reference values. Software pro-
viding these features is currently implemented in onco-
logical in- and outpatients units in several hospitals in
Austria [50-52].
Conclusion
The present study underlines the importance of longitu-
dinal assessment of QOL in order to facilitate the iden-
tification of symptom burden in OC patients over the
course of treatment. We found that patients show high
levels of fatigue, anxiety and depressive symptoms and
severely impaired QOL post-surgery (i.e. at start of che-
motherapy) but their condition improves considerably
throughout chemotherapy reaching nearly general popu-
lation symptoms levels until aftercare. To support medi-
cal as well as psycho-oncological symptom management,
routinely conducted QOL monitoring is recommended.
In future research, especially the course of QOL and
psychosocial issues for long-term survivors of OC
require further investigation.
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